# Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

> **NCT05649163** · — · UNKNOWN · sponsor: **Shen Lin** · enrollment: 306 (estimated)

## Conditions studied

- HER2
- Advanced Gastric Cancer
- Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** Disitamab Vedotin

## Key facts

- **NCT ID:** NCT05649163
- **Lead sponsor:** Shen Lin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2025-01
- **Final completion:** 2025-05
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2022-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649163, "Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05649163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*